[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123)/Sixth communication: Results of compatibility of CN 3123 (author's transl)].
1. During the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) side-effects were reported in only 56 (=4.1%) of the 1371 patients who took part. 2. The numerous laboratory parameters studied in the whole group and in the group which received long-term treatment did not show any significant changes due to CN 3123. 3. The frequency and the type of side-effects which occurred under the combined preparation CN 3123 were the same as those known to be caused by sulfonamide treatment. 4. The good tolerance, which is a familial feature of sulfonamide treatment, is not impaired when sulfamoxole is combined with trimethoprim.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000097:blood; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007223:Infant; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D013423:Sulfamoxole / Q000009:adverse effects*; D013961:Thyroid Gland / Q000187:drug effects; D014280:Triglycerides / Q000097:blood; D014295:Trimethoprim / Q000009:adverse effects*
D001786:Blood Glucose; D004338:Drug Combinations; D014280:Triglycerides; D014295:Trimethoprim; D013423:Sulfamoxole
Klinische Prüfung der antibakteriellen Kombination Sulfamoxol/Trimethoprim (CN 3123). 6. Mitteilung: Ergebnisse zur Verträglichkeit von CN 3123